Korean biopharmaceutical firm Alzheimer’s Disease Experts Lab is accelerating its drug development for the brain disease targeting tau proteins.
ADEL is currently developing antibody therapy candidate ADEL-Y01, which is designed to detect tau -- a brain protein creating toxic tangles inside nerve cells of people with Alzheimer’s disease.
|ADEL CEO Yoon Seung-yong|
The potential drug is being developed to treat several other indications for neurodegenerative diseases such as frontotemporal dementia, progressive supranuclear palsy and corticobasal degeneration.
Intracellular tau protein tangles and extracellular amyloid plaques are two defining pathological hallmarks of Alzheimer‘s disease. So far, all clinical trials of new drugs to combat Alzheimer’s by preventing the formation of amyloid plaque in the brain have failed.
“ADEL-Y01 is an antibody that targets specific epitope that have the best memory and pathological improvements in animal models with dementia,” CEO Yoon Seung-yong said.
On Nov. 26, the company said the drug development project has been awarded funding from the Korea Drug Development Fund, a government-initiated drug development program.
ADEL was founded in December last year by Yoon, professor at Brain Research Center, University of Ulsan College of Medicine.
By Park Han-na (firstname.lastname@example.org)